Quantinno Capital Management LP Boosts Stock Position in Fresenius Medical Care AG & Co. KGaA $FMS

Quantinno Capital Management LP increased its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 15.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 341,343 shares of the company’s stock after purchasing an additional 46,428 shares during the period. Quantinno Capital Management LP’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $7,701,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Sei Investments Co. grew its holdings in Fresenius Medical Care AG & Co. KGaA by 80.7% during the 1st quarter. Sei Investments Co. now owns 120,704 shares of the company’s stock worth $2,723,000 after acquiring an additional 53,922 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 76.7% in the 1st quarter. Cetera Investment Advisers now owns 15,917 shares of the company’s stock valued at $359,000 after purchasing an additional 6,909 shares in the last quarter. Barometer Capital Management Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 569.6% in the 1st quarter. Barometer Capital Management Inc. now owns 46,200 shares of the company’s stock valued at $1,042,000 after purchasing an additional 39,300 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in the 1st quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock worth $104,000 after purchasing an additional 1,011 shares during the period. Finally, Assetmark Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% in the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock worth $2,985,000 after purchasing an additional 86,798 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $23.91 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.86 and a current ratio of 1.07. The company has a market cap of $12.84 billion, a PE ratio of 12.39, a P/E/G ratio of 4.27 and a beta of 0.77. The business has a 50-day simple moving average of $23.49 and a two-hundred day simple moving average of $22.99. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04. The firm had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FMS has been the topic of several research reports. Sanford C. Bernstein assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Thursday, July 16th. They set a “market perform” rating on the stock. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a report on Tuesday, July 28th. Finally, Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Six investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $22.45.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.